// App-Quantinova.ai

51 : A Phase 2 Study of the LSD1 Inhibitor IMG7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Researchers

Presenter

  • Abdulraheem Yacoub

Principal Investigators

  • Terrence J Bradley

  • Aaron T. Gerds

  • Maciej Tartaczuch

  • Jake Shortt

  • Natasha Joan Curtin

  • James M. Rossetti

  • Kate Burbury

  • Adam J. Mead

  • Joachim R Gthert

  • Steffen Koschmieder

  • Amber Jones

  • Jennifer Peppe

  • Georges Natsoulis

  • William S. Stevenson

  • Joanne Ewing

  • Claire Harrison

  • Alessandro Vannucchi

  • Justin M Watts

  • David M Ross

  • Moshe Talpaz

  • Hugh Young Rienhoff Jr

Medical Centers

  • University of Kansas Medical Center, Westwood, KS

  • Comprehensive Cancer Center, University of Michigan, Grass Lake, MI

  • University of Miami/Sylvester Cancer Center, Miami, FL

  • Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

  • School of Clinical Sciences, Monash University, Melbourne, Australia

  • Department of Nephrology, Monash Health, Clayton, Vic, Australia

  • Monash Health and Monash University, Melbourne, Australia

  • UPMC Cancer Center, Pittsburgh, PA

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Weatherall Institute of Molecular Medicine, Oxford, United Kingdom

  • Department of Surgery, Westgerman Cancer Center, University Hospital Essen, Essen, Germany

  • Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, RWTH Aachen University Hospital, Aachen, Germany

  • Imago Biosciences, Inc., San Carlos, CA

  • Imago Biosciences, Inc., San Carlos, CA

  • Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, New South Wales, Australia

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Department of Haematology, Guys and St Thomas Hospitals NHS Trust, London, United Kingdom

  • CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

  • University of Miami, Coral Gables, FL

  • Haematology,Flinders Medical Centre and University,Adelaide,Australia

  • University of Michigan Medical School, Ann Arbor, MI

  • Imago Biosciences, San Francisco

Locations

  • United States

  • Australia

  • United Kingdom

  • Germany

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

  • Congestive heart failure

  • Anemia

  • Myeloid neoplasms

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • Calreticulin

  • C-C Motif Chemokine Ligand 5

  • Interleukin-8

  • Lysine-specific histone demethylase 1A

  • Sustained virological response

Drug/Treatment

  • Ruxolitinib phosphate

  • Fedratinib

  • CPI-0610

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved